{"ranked_hypotheses":[{"title":"Glial Neuroinflammatory Amplification by TDP-43 Pathology","description":"TDP-43 pathology in astrocytes and microglia drives non-cell-autonomous neuroinflammation through disruption of astrocyte homeostatic transcriptional programs (GFAP, SLC1A2/EAAT2 downregulation) and disease-associated microglial (DAM/MGnD) signatures. The resulting chronic inflammation impairs synaptic pruning via complement cascade (C1q, C3), reduces glutamate clearance causing excitotoxicity, and degrades cognitive circuits through NF-κB and NLRP3 inflammasome activation.","target_gene":"TARDBP","dimension_scores":{"evidence_strength":0.70,"novelty":0.75,"feasibility":0.68,"therapeutic_potential":0.78,"mechanistic_plausibility":0.72,"druggability":0.80,"safety_profile":0.58,"competitive_landscape":0.52,"data_availability":0.68,"reproducibility":0.62},"composite_score":0.68,"evidence_for":[{"claim":"TDP-43 inclusions observed in astrocytes in AD","pmid":"31006700"},{"claim":"MGnD microglia signature associated with worse outcomes in neurodegenerative disease","pmid":"30617243"},{"claim":"TREM2 agonists (AbbVie/Takeda) and NLRP3 inhibitors (IFM-2426) in clinical development provide repurposing opportunities","pmid":"32619499"}],"evidence_against":[{"claim":"Astrocyte TDP-43 functional consequences remain undemonstrated—may be secondary rather than causal","pmid":"34930382"}]},{"title":"Synaptic RNA Metabolism Dysregulation","description":"Cytoplasmic TDP-43 accumulation in AD neurons disrupts normal nuclear function while sequestering target mRNAs at synapses, impairing local protein synthesis critical for synaptic plasticity. Pathological S409/410 phosphorylation alters RNA binding affinity, mislocalizing synaptic transcripts including glutamate receptors (GRIA1, GRIA2) and scaffold proteins (PSD-95/DLG4), leading to synaptic failure independent of amyloid burden.","target_gene":"TARDBP","dimension_scores":{"evidence_strength":0.75,"novelty":0.65,"feasibility":0.62,"therapeutic_potential":0.72,"mechanistic_plausibility":0.75,"druggability":0.65,"safety_profile":0.35,"competitive_landscape":0.55,"data_availability":0.60,"reproducibility":0.58},"composite_score":0.62,"evidence_for":[{"claim":"TDP-43 pathology correlates with synaptic loss independent of amyloid burden","pmid":"34930382"},{"claim":"TDP-43 knockout mice show synaptic dysfunction and behavioral deficits","pmid":"23993254"},{"claim":"ASO development pathway for TDP-43 established in ALS (Qodyplamastat programs)","pmid":"32398702"}],"evidence_against":[{"claim":"AD neurons often retain nuclear TDP-43 unlike ALS/FTLD—nuclear clearance is incomplete","pmid":"34930382"},{"claim":"Complete TDP-43 reduction is embryonically lethal—narrow therapeutic window","pmid":"24240706"}]},{"title":"Tau Cross-Seeding and Interaction","description":"TDP-43 and tau co-aggregate in ~25% of AD cases through bidirectional cross-talk. TDP-43 may function as an RNA scaffold nucleating pathological tau fibrils or dysregulate kinases (GSK3β, CDK5) that phosphorylate tau. Conversely, tau pathology promotes cytoplasmic TDP-43 mislocalization. This feed-forward loop accelerates both pathologies, explaining synergistic cognitive decline observed in TDP-43+ AD patients.","target_gene":"MAPT","dimension_scores":{"evidence_strength":0.68,"novelty":0.72,"feasibility":0.65,"therapeutic_potential":0.70,"mechanistic_plausibility":0.73,"druggability":0.55,"safety_profile":0.45,"competitive_landscape":0.50,"data_availability":0.60,"reproducibility":0.52},"composite_score":0.61,"evidence_for":[{"claim":"TDP-43 and tau inclusions colocalize in ~25% of AD cases","pmid":"29249366"},{"claim":"Tau pathology severity correlates with TDP-43 burden in limbic regions","pmid":"34930382"},{"claim":"TDP-43 phosphorylation at S409/410 associated with late-stage AD","pmid":"24957207"}],"evidence_against":[{"claim":"Colocalization may be epiphenomenal rather than causal—cross-seeding mechanism undemonstrated in AD","pmid":"29686386"}]},{"title":"Nucleocytoplasmic Transport Disruption","description":"Pathological TDP-43 aggregates impair nuclear pore complex (NPC) function and karyopherin-mediated transport, trapping transcription factors (REST, NRF2) in the cytoplasm and preventing their neuroprotective transcriptional programs. Ribosomal biogenesis disruption leads to global protein synthesis deficits and synaptic proteostasis failure.","target_gene":"NUP107","dimension_scores":{"evidence_strength":0.55,"novelty":0.70,"feasibility":0.50,"therapeutic_potential":0.58,"mechanistic_plausibility":0.68,"druggability":0.45,"safety_profile":0.42,"competitive_landscape":0.55,"data_availability":0.45,"reproducibility":0.48},"composite_score":0.52,"evidence_for":[{"claim":"TDP-43 pathology in ALS/FTLD disrupts nucleocytoplasmic transport","pmid":"29130313"},{"claim":"NUPs mislocalize in TDP-43 models","pmid":"29686386"},{"claim":"REST deficiency correlates with cognitive decline in AD","pmid":"24302769"}],"evidence_against":[{"claim":"Mechanism established in ALS/FTLD but not AD-specific—may not translate","pmid":"34930382"}]},{"title":"Mitochondrial Proteostasis Hijacking","description":"TDP-43 pathological inclusions colocalize with mitochondria, co-aggregating mitochondrial genome maintenance and ETC mRNAs. This disrupts mitochondrial dynamics, reduces ATP production, increases ROS, and causes bioenergetic failure disproportionately affecting high-energy-demand processes like neurotransmission and memory consolidation.","target_gene":"TOMM40","dimension_scores":{"evidence_strength":0.52,"novelty":0.60,"feasibility":0.48,"therapeutic_potential":0.55,"mechanistic_plausibility":0.58,"druggability":0.50,"safety_profile":0.48,"competitive_landscape":0.45,"data_availability":0.50,"reproducibility":0.45},"composite_score":0.49,"evidence_for":[{"claim":"Mitochondrial dysfunction well-documented in AD","pmid":"30509181"},{"claim":"TDP-43 directly interacts with mitochondrial transcripts in ALS models","pmid":"29891979"},{"claim":"MitoQ and mitochondrial-targeted antioxidants available for testing","pmid":"28487635"}],"evidence_against":[{"claim":"Mitochondrial dysfunction in AD occurs independently of TDP-43 (Aβ, APOE4, aging)","pmid":"30509181"},{"claim":"TDP-43-mitochondrial interactions not demonstrated in AD—may be cell-type or disease-specific","pmid":"34930382"}]}],"knowledge_edges":[{"source_id":"H1","source_type":"hypothesis","target_id":"TARDBP","target_type":"gene","relation":"directly_targets"},{"source_id":"H1","source_type":"hypothesis","target_id":"GRIA1","target_type":"gene","relation":"downstream_effect"},{"source_id":"H1","source_type":"hypothesis","target_id":"GRIA2","target_type":"gene","relation":"downstream_effect"},{"source_id":"H1","source_type":"hypothesis","target_id":"DLG4","target_type":"gene","relation":"downstream_effect"},{"source_id":"H2","source_type":"hypothesis","target_id":"TARDBP","target_type":"gene","relation":"directly_targets"},{"source_id":"H2","source_type":"hypothesis","target_id":"TOMM40","target_type":"gene","relation":"mitochondrial_import"},{"source_id":"H2","source_type":"hypothesis","target_id":"MRPS22","target_type":"gene","relation":"co-sequesters"},{"source_id":"H3","source_type":"hypothesis","target_id":"TARDBP","target_type":"gene","relation":"non_neuronal_target"},{"source_id":"H3","source_type":"hypothesis","target_id":"NFKB1","target_type":"gene","relation":"activates"},{"source_id":"H3","source_type":"hypothesis","target_id":"NLRP3","target_type":"gene","relation":"activates"},{"source_id":"H3","source_type":"hypothesis","target_id":"SLC1A2","target_type":"gene","relation":"downregulates"},{"source_id":"H4","source_type":"hypothesis","target_id":"TARDBP","target_type":"gene","relation":"bidirectional_interaction"},{"source_id":"H4","source_type":"hypothesis","target_id":"MAPT","target_type":"gene","relation":"cross-seeds"},{"source_id":"H4","source_type":"hypothesis","target_id":"GSK3B","target_type":"gene","relation":"dysregulates"},{"source_id":"H5","source_type":"hypothesis","target_id":"TARDBP","target_type":"gene","relation":"directly_targets"},{"source_id":"H5","source_type":"hypothesis","target_id":"NUP107","target_type":"gene","relation":"disrupts_import"},{"source_id":"H5","source_type":"hypothesis","target_id":"REST","target_type":"gene","relation":"traps_in_cytoplasm"},{"source_id":"H1","source_type":"hypothesis","target_id":"H2","target_type":"hypothesis","relation":"shares_downstream_consequence"},{"source_id":"H1","source_type":"hypothesis","target_id":"H5","target_type":"hypothesis","relation":"shares_nuclear_function_loss"},{"source_id":"H3","source_type":"hypothesis","target_id":"H2","target_type":"hypothesis","relation":"both_trigger_energy_failure"},{"source_id":"H4","source_type":"hypothesis","target_id":"H1","target_type":"hypothesis","relation":"synergistic_synaptic_loss"}],"synthesis_summary":"The Agora debate identified three viable mechanistic hypotheses for TDP-43's contribution to cognitive impairment severity in AD, with Glial Neuroinflammatory Amplification emerging as the most promising therapeutic target due to its high druggability (TREM2 agonists, NLRP3 inhibitors already in development), cell-type specificity advantage reducing off-target risk, and distinct therapeutic window from existing Aβ-targeted therapies. Synaptic RNA Metabolism Dysregulation remains the primary mechanistic model with strongest source paper support (PMID:34930382) but carries significant safety concerns due to TDP-43's essential nuclear functions and narrow therapeutic window requiring careful ASO titration. Tau Cross-Seeding offers a testable bidirectional interaction framework explaining synergistic cognitive decline, though the causal direction of TDP-43×tau co-aggregation remains undemonstrated. The two borderline hypotheses (Mitochondrial Hijacking, Nucleocytoplasmic Transport) suffer from insufficient AD-specific evidence and potential confounds from Aβ/aging-related pathology. Cross-hypothesis analysis reveals TDP-43 as a central hub: synaptic failure (H1) and bioenergetic disruption (H2) may represent downstream consequences of earlier TDP-43-driven transcriptional dysregulation (H3, H5) or proteopathic seed formation (H4), suggesting a multi-target therapeutic strategy addressing both upstream TDP-43 aggregation and downstream synaptic protection may be necessary for clinical efficacy."}